RxDoctor Payments Data

Mena Samaan, MD

Vascular Neurology · Fayetteville, NCNPI 1437590320

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $7,496 of the $12,245 with a category attached, or 61.2%. 13 manufacturers reported payments, led by Penumbra, Inc. at 33.9% of the total. Reporting peaked in 2022 at $5,242 and has fallen 95.4% since, to $240 in 2025.

$12,245in general payments, 2019–2025

Across 119 payments — averaging $102.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$4K
  • Microvention, Inc.$2K
  • Medtronic$2K
  • Medical Device Business Services, Inc.$2K
  • Stryker$1K
  • Imperative Care, Inc$659
  • plus $510 from 7 others

What the payments were for

  • Travel & lodging$7,49661%
  • Food & beverage$4,74539%
  • Gifts$40%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$70,690
Medicare patients
125
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$43,842
BrilintaTicagrelor32$19,444
Atorvastatin Calcium150$1,760
ClopidogrelClopidogrel Bisulfate108$1,030
Pantoprazole Sodium99$961
Famotidine21$517
Levetiracetam15$473
Rosuvastatin Calcium20$149
Baclofen13$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$43,84250 claims
AstraZenecaBrilinta$14$19,44432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other vascular neurology in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →